SYNTHEGO CORPORATION

Synthego Corporation specializes in advanced gene-editing services and biotechnology research, delivering precision CRISPR-based solutions for academic and federal research programs. Their core capabilities include the design and generation of custom knock-in and knock-out cell lines, immortalized cell models, and induced pluripotent stem cell (iPSC) engineering, alongside the production of synthetic guide RNA (sgRNA) libraries and high-throughput screening platforms for gene expression modulation. The company excels in molecular biology workflows involving genome editing in human cell lines, particularly for targets such as ACVR1, TGFBR1, HIF1, and HIF2, supporting functional genomics and disease modeling. Their technical differentiation lies in scalable, reproducible gene-editing platforms tailored to complex cellular contexts, enabling downstream cell biology and therapeutic discovery efforts. Synthego maintains a consistent and deep relationship with the Department of Health and Human Services, providing mission-critical gene-editing and laboratory services across multiple institutes including NIAAA, NICHD, NHGRI, and NIDCR. Their work supports fundamental research in cancer biology, neurology, and metabolic disease, often delivering engineered cell models and molecular reagents that serve as foundational tools for investigator-led studies. The company’s primary industry focus is in biotechnology research and development (NAICS 541714) and testing laboratory services (541380), with secondary capabilities in biological product manufacturing and organic chemical synthesis. They position themselves as a specialized provider of engineered biological tools for government-funded life sciences research, bridging the gap between academic inquiry and preclinical development. Synthego Corporation is a small business entity headquartered in Redwood City, California. While currently holding no formal government certifications, its technical reputation and consistent performance with HHS agencies establish a strong foothold in the federal bioresearch market.